KPV
Lysine-proline-valine
A three amino acid fragment of a pigment hormone, sold as a cream for inflammation.
KPV is the shortest peptide the FDA has ever taken to a compounding vote, and the one with the least behind it. Nobody has published giving it to a human being by any route. It was nominated as a 0.1 percent cream for wound healing and inflammatory conditions, and it is sold online as injections, capsules, creams and nasal sprays for everything from bowel disease to stroke. In July 2026 an FDA advisory committee recommended it for pharmacy compounding anyway, against the agency's own reviewers.
Where it stands, jurisdiction by jurisdiction
United States
Unregulated, unregulated, sold anywayDecided on: Precaution, Contested
Not a lawful dietary ingredient and not on the 503A list pharmacies may compound from. FDA found no clinical study, no pharmacokinetic data, no adverse event report and no human exposure of any kind, so it said the safety risks are unknown rather than low. Its one relevant laboratory finding cuts both ways: in human cadaver skin KPV barely penetrates, which limits both the harm and the point of a cream. The advisory committee recommended adding it 8 to 6 with one abstention on 23 July 2026, but that vote is not a rule change and KPV remains off the list.
Regulatory positions change, sometimes quickly. Check the date on a source before relying on it.